Cytokinetics CYTK Rights Granted — Nonrefundable Payment Obligation
Discontinued — last reported Q4 '21
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept cytk:NonrefundablePaymentObligation.
The official record: Cytokinetics’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's rights granted — nonrefundable payment obligation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's rights granted — nonrefundable payment obligation?
- Cytokinetics (CYTK) reported rights granted — nonrefundable payment obligation of $40M in Q4 2021.
- What does rights granted — nonrefundable payment obligation mean?
- Revenue or deferred income generated from licensing intellectual property or granting development rights to external partners.
- How do you interpret rights granted — nonrefundable payment obligation?
- An increase indicates successful monetization of the R&D pipeline and strong external validation of the company's technology, while a decrease may suggest a slowdown in partnership activity or licensing opportunities.
- How does rights granted — nonrefundable payment obligation compare across companies?
- Common in biotechnology and pharmaceutical companies that utilize a partnership-based business model to fund clinical trials and commercialize drug candidates.